Abstract:IMPORTANCE Loss of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression has been reported in several malignant tumors and predicts dismal survival outcomes. In gastric cancer, existing studies on this topic are limited and the association between MGMT and fluorouracil-based adjuvant chemotherapy remains obscure. OBJECTIVE To investigate the postoperative prognostic significance of MGMT in patients with resectable gastric cancer and its responsiveness to fluorouracil-based adjuvant chemotherapy. DESIGN, SETTING, AND PARTICIPANTS This study recruited 445 consecutive patients with resectable gastric cancer who underwent radical gastrectomy between August 1, 2007, and December 30, 2008, at Zhongshan Hospital at Fudan University in Shanghai, China. Patients were randomly divided into a discovery data set (n = 200) and a validation data set (n = 245), and the range of follow-up time was from 2 to 76 months for the discovery group and 2 to 79 months for the validation group. The immunoreactivity for MGMT in cancer cells was reviewed under a light microscope by 2 pathologists who were blinded to the clinicopathological data. The association of MGMT expression with clinicopathological characteristics and measures and prognosis was inspected. Data and specimens were collected from patients from the date of surgery to April 25, 2014. Data analysis took place from May 9, 2016, to July 15, 2016. MAIN OUTCOMES AND MEASURES Estimates of overall survival on the basis of MGMT expression and hazard ratio (HR) for estimates of overall mortality risk. RESULTS Of the 445 patients included in the study, 315 (70.8%) were men, and the mean (SD) age of all patients was 60 (12) years. Positive expression of MGMT indicated better overall survival for patients with stage II or III gastric cancer in both the discovery data set (HR, 0.52; 95% CI, 0.32-0.84; P =.003) and the validation data set (HR, 0.63; 95% CI, 0.43-0.93; P =.01). Multivariate analysis identified MGMT expression and TNM stage as 2 independent prognostic factors for overall survival. In stage II disease, the benefit from fluorouracil-based adjuvant chemotherapy was superior among MGMT-positive patients (HR, 0.35; 95% CI, 0.13-0.95; P =.007 for interaction) compared with MGMT-negative patients. CONCLUSIONS AND RELEVANCE Positive expression of MGMT in gastric cancer was identified as an independent, favorable prognostic factor. Incorporating MGMT expression into the current TNM staging system could lead to better prognostic accuracy. These findings should be confirmed within the framework of randomized clinical trials associated with genomic DNA sequencing studies.

Expression and clinical significance of O6-methylguanine DNA methyltransferase in cervical cancer tissues

O6-methylguanine DNA Methyltransferase is Upregulated in Malignant Transformation of Gastric Epithelial Cells Via Its Gene Promoter DNA Hypomethylation

Expression of O6-methylguanine-DNA Methyltransferase in Transitional Cell Carcinoma of the Bladder and Its Clinical Significance

Expressions and the Clinical Significance of MGMT, Hmlh1 in Human Gastric Carcinoma

Amino acid substitution polymorphisms of the DNA repair gene MGMT and the susceptibility to cervical carcinoma.

The relationships between the expression of MGMT and prognosis in the advanced patients with gastric carcinoma

[The Expression of O6-methylguanine DNA Methyltransferase and P53 in Non-Small Cell Lung Cancer and the Association with the Prognosis].

Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.

O-6-Methylguanine-Dna Methyltransferase (Mgmt): Challenges And New Opportunities In Glioma Chemotherapy

Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm.

O6-Methylguanine-DNA Methyltransferase Activity in Human Tumors

Implications of Advances in Studies of O6-Methylguanine-DNA- Methyltransferase for Tumor Prognosis and Treatment

Expression of MGMT in Hepatocellular Carcinoma and Their Clinical Significance

Promoter Hypermethylation of DNA Repair Gene O~6- methylguanine DNA Methyltransferase in Gliomas

Expression and clinical value of MGMT and EGFR in laryngeal squamous cell carcinoma

Detailed methylation patterns and protein expression profiles of MGMT in colorectal carcinoma surgical margins.

A Systematic Review and Meta-Analysis: Association Between MGMT Hypermethylation and the Clinicopathological Characteristics of Non-Small-cell Lung Carcinoma.

MGMT in Colorectal Cancer: a Promising Component of Personalized Treatment.

Progress on Study of MGMT Expression in Human Gliomas

The Hypermethylation and Protein Expression of P16(Ink4a) and Dna Repair Gene O-6-Methylguanine-Dna Methyltransferase in Various Uterine Cervical Lesions

Prognostic and Predictive Value of O 6 -Methylguanine Methyltransferase for Chemotherapy in Patients with Muscle-Invasive Bladder Cancer